Aug 02,2023

British Columbia expands public coverage of type 1 diabetes technologies to include a flash glucose monitoring device

The Government of British Columbia announced yesterday that the FreeStyle Libre, a flash glucose monitoring (Flash GM) device, will be covered by BC PharmaCare as a limited-coverage benefit for people living with type 1 diabetes (T1D) beginning August 1st 2023. Prior to this announcement, public coverage in British Columbia was limited to only the Dexcom G6 continuous glucose monitor (CGM). In British Columbia, it is estimated that 34,000 people live with T1D. Use of devices like Flash GMs have been shown to reduce hospitalizations and the risk of longer-term complications for its users. Through its #AccessForAll advocacy campaign, JDRF Canada has been working to help make a variety of T1D technologies affordable and accessible for all Canadians living with the disease.

PRODUCT

#reimbursement

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 07,2023

The Development of Digital Therapies as a New Therapeutic Option to Treat Diseases: Focus on the International Regulatory Framework

The development of digital therapies (DTx) has attracted considerable attention in the scientific community worldwide. DTx are software-based therapeutic interventions specifically designed to prevent, manage, or treat various diseases directly in patients. Given the limited available sources on this topic in the current international scientific literature, the purpose of this review is to provide an overview of the definition and history leading up to the marketing of DTx, as well as to categorize the major DTx currently on the market on the basis of indications and mechanisms of action, with a focus on the regulatory processes that have enabled their use in clinical practice.

CLINICAL STUDY

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Jan 04,2022

CPT Code granted by American Medical Association to LungLife AI

LungLife AI, a developer of clinical diagnostic solutions for lung cancer announces it has been granted a CPT Proprietary Laboratory Analyses (PLA) code for its LungLB test by the American Medical Association (AMA). The new code has been approved and published by the AMA Editorial Panel and is scheduled to become effective on 1 April 2022. The successful granting of a CPT code marks the first step on the path for commercial reimbursement.

PRODUCT

#reimbursement

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 03,2023 TOP STORY

Oviva Direct for Obesity now permanently available in DiGA

Oviva Direkt for Obesity, an app for weight reduction in cases of obesity, has been permanently added to the list of digital health applications (DiGA) by the German Federal Institute for Drugs and Medical Devices (BfArM). The app provides step-by-step support for adopting a healthier lifestyle and has been proven effective in a clinical trial. It aims to fill gaps in the care of people with obesity and is now available on prescription in Germany.

PRODUCT

#reimbursement

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 06,2023 TOP STORY

Medicare now covers new Medtronic MiniMed 780G automated insulin pump

Medtronic announced today that Medicare now covers its new MiniMed 780G system with the Guardian 4 sensor. Coverage for the recently FDA-approved automated insulin delivery system extends to all eligible Medicare and Medicare Advantage beneficiaries. The company plans to start shipments to eligible recipients with type 1 diabetes over the next few weeks. The MiniMed 780G system features SmartGuard technology and Meal Detection Technology, providing automatic adjustments to sugar levels without fingersticks and optimizing insulin delivery. Medtronic presented positive data on the system's Meal Time Technology at the American Diabetes Association Scientific Sessions.

PRODUCT

#cgm

#insulin pump

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Jun 09,2023 TOP STORY

Digital Therapeutics Alliance and Healthware published a report on digital therapeutics policy pathways in Europe

Healthware, and the Digital Therapeutics Alliance today announced the release of a report outlining policy pathways for digital health adoption in Europe. The free to donwload report provides information and clarity around the evolving landscape of digital therapeutics and particularly the policies and reimbursement pathways.

#reimbursement

View Analyst & Ambassador Comments
Go to original news
May 12,2023

Q&A: Digital therapeutics' future after the fall of Pear Therapeutics

The CEO of the Digital Therapeutics Alliance, Andy Molnar, discusses the impact of Pear Therapeutics' bankruptcy on the digital therapeutics market. Despite challenges in funding and standards of care, Molnar believes that digital therapeutics are here to stay and will continue to progress. He emphasizes the importance of provider adoption, payer reimbursement, and government support in driving the advancement of digital therapeutics.

#reimbursement

#pdt

View Analyst & Ambassador Comments
Go to original news
Apr 04,2023

Advocates of Digital Therapies Hope Bill Can Ease Reimbursement

Advocates of prescription digital therapeutics are hopeful that a newly reintroduced bill in Congress, the Access to Prescription Digital Therapeutics Act, will ease reimbursement for these innovative treatments. The legislation, which covers both physical and behavioral health, aims to create reimbursement codes for prescription digital therapeutics, providing a clearer pathway for commercial payers and potentially accelerating the reimbursement process. Advocates argue that these therapies have the potential to save costs while expanding access to critical behavioral healthcare. Bipartisan support for the bill has been seen, but its passage and estimated costs by the Congressional Budget Office are still awaited

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Mar 21,2023

AppliedVR Becomes First Virtual Reality Provider to Receive HCPCS Level II Code from Centers for Medicare and Medicaid Services as Durable Medical Equipment

AppliedVR, an immersive therapeutics (ITx) company, has become the first virtual reality provider to receive a Healthcare Common Procedure Coding System (HCPCS) Level II code from the Centers for Medicare and Medicaid Services (CMS) for its flagship product, the RelieVRx program. The HCPCS code, which categorizes the program as durable medical equipment (DME), allows AppliedVR's digital therapeutic (DTx) solution to have a clearer pathway for securing Medicare coverage eligibility and could influence commercial coverage more broadly. The RelieVRx program provides virtual reality cognitive behavioral therapy (CBT) to treat chronic low back pain and was the first VR-based therapeutic to receive FDA authorization

PRODUCT

#virtual reality

#reimbursement

#cbt

View Analyst & Ambassador Comments
Go to original news
Mar 09,2023

DTA Applauds the Reintroduction of Bipartisan Legislation to Enable Public Coverage of Prescription Digital Therapeutics

The Digital Therapeutics Alliance (DTA), a global non-profit trade association representing digital therapeutics (DTx) companies, has praised the reintroduction of bipartisan legislation that would enable public coverage of prescription digital therapeutics in the United States. The bill, known as the Prescription Digital Therapeutic (PDT) Act, would create a pathway for DTx products to be prescribed by healthcare providers and reimbursed by public health insurance programs like Medicare and Medicaid. The DTA believes this will help ensure that patients have access to effective, safe and affordable DTx treatments, which can help improve clinical outcomes and reduce healthcare costs.

#reimbursement

#pdt

View Analyst & Ambassador Comments
Go to original news
Subscribe to REIMBURSEMENT